文献速递外周动脉疾病

开放与腔内治疗TASC II D型主髂动脉闭塞性疾病的结局比较

Outcome Comparison between Open and Endovascular Management of TASC II D Aortoiliac Occlusive Disease.
PubMed 文献 · Ann Vasc Surg · 2019-08-06

该回顾性研究纳入75例TASC II D型主髂动脉闭塞患者,比较开放手术与腔内治疗的短期和中期结局。腔内组围手术期全身并发症更少,但再干预率更高,2年一期通畅率低于开放组。

要点

  • 开放组总体并发症(43.3% vs 17.8%)和围手术期全身并发症(40.0% vs 6.7%)显著更高。
  • 腔内组再干预率显著更高(20.0% vs 3.3%),2年一期通畅率显著更低(80.0% vs 96.7%)。
  • 腔内治疗初始技术成功率高,两组技术并发症无显著差异。

核心结论

  • 对于复杂主髂动脉闭塞性疾病,腔内治疗初始技术成功率高且院内全身并发症少,但再干预率高于开放手术。
  • 开放手术2年一期通畅率显著优于腔内治疗。

研究设计与样本

  • 开放组30例,腔内组45例;腔内组中25例(55.6%)采用杂交方法。
  • 主要结局为一期通畅率,采用Kaplan-Meier曲线分析随访结果。

主要发现

  • 开放组总体并发症发生率显著更高(43.3% vs 17.8%,OR 3.5,95%CI 1.2-10.1,P=0.016)。
  • 开放组围手术期全身并发症更常见(40.0% vs 6.7%,OR 9.3,95%CI 2.3-37.3,P<0.001)。
  • 两组技术并发症无显著差异(6.7% vs 11.1%,OR 0.6,95%CI 0.1-3.1,P=0.517)。
  • 腔内组再干预率显著更高(20.0% vs 3.3%,OR 7.2,95%CI 1.1-14.3,P=0.038)。
  • 开放组2年一期通畅率显著更高(96.7% vs 80.0%,OR 7.2,95%CI 1.2-60.5,P=0.038)。

关键数值与推荐

  • 腔内组初始技术成功率为100%。
  • 重症肢体缺血为干预指征者占16.0%(开放13.3% vs 腔内17.8%,P=0.397)。
  • 随访数据完整者68例(90.7%),平均随访21.3±17.1个月(范围1-72个月)。

临床怎么用

  • 腔内治疗可作为TASC II D型主髂动脉闭塞的选择,但需告知再干预风险较高。
  • 开放手术通畅率更优但全身并发症风险更高,应个体化选择。

局限性

  • 回顾性研究,样本量较小(75例)。
  • 腔内组中55.6%采用杂交方法,可能影响组间可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular management of complex aortoiliac occlusive disease (AIOD) has been described as a viable alternative to open surgical reconstruction. To date, few studies have directly compared the 2 techniques. We therefore, evaluated short and mid- term outcomes of open and endovascular therapy in TASC II D AIOD patients. METHODS: TASC II D patients undergoing treatment between January 2009 and December 2016 were retrospectively reviewed. Patient demographics, clinical data, and outcomes (complications [technical and systemic] and graft patency) were collected. The primary outcome of this study was primary graft patency. Patients were compared according to treatment group (open versus endovascular). Kaplan-Meier curves were used to analyze follow up results. RESULTS: A total of 75 consecutive patients (open: 30; endovascular: 45) were included in this analysis. In the endovascular group, 25 (55.6%) patients were managed using a hybrid approach with 100% technical success. Critical limb ischemia was the indication for intervention in 16.0% of this cohort (open, 13.3% vs. endovascular, 17.8%, P = 0.397). Overall, there were no significant differences in gender (male: open, 50.0% vs. endovascular, 55.6%, P = 0.637) or age (54.5 ± 5.9 years vs. 57.0 ± 8.7 years, P = 0.171). No in hospital deaths occurred in this cohort. The overall complication rate was significantly higher in the open group (43.3% vs. 17.8%, OR 3.5, 95% CI [1.2-10.1], P = 0.016) with peri-operative systemic complications being more likely in the open cohort (40.0% vs. 6.7%, OR 9.3, 95% CI [2.3-37.3], P < 0.001) while technical complications did not differ between the 2 groups (6.7% vs. 11.1%, OR 0.6, 95% CI [0.1-3.1], P = 0.517). Follow up data was available for 68 patients (90.7%), for a mean of 21.3 ± 17.1 months (range: 1-72 months). Re-intervention rates were significantly higher in the endovascular group (3.3% vs. 20.0%, OR 7.2, 95% CI [1.1-14.3], P = 0.038). The overall primary patency at 2 years was significantly higher in the open group (96.7% vs. 80.0%, OR 7.2, 95% CI [1.2-60.5], P = 0.038). Cox regression analysis revealed separation of the primary outcome for open therapy relative to endovascular repair (log rank, P = 0.320). CONCLUSIONS: In this comparison of open and endovascular therapy for complex AIOD, endovascular therapy was associated with high initial technical success and fewer in-hospital systemic complications but also high re-intervention rates when compared to open repair. Further prospective studies aimed at reduction of complications, optimization of patency, and patient selection for such procedures is warranted.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Mayor J, Branco BC, Chung J, et al. Outcome Comparison between Open and Endovascular Management of TASC II D Aortoiliac Occlusive Disease. Ann Vasc Surg. 2019. PMID: 31394230. doi:10.1016/j.avsg.2019.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。